Advertisements



Flex Pharma Shares Plunge After Biotech Ends 2 Clinical Trials, Announces 60% Workforce Cut

Flex Pharma Inc (NASDAQ: FLKS) shares are slumping on above-average volume Wednesday following a release from the company announcing the scrapping of two clinical trials and the explo read more.....»»

Category: blogSource: benzingaJun 13th, 2018

Flex Pharma Down on Workforce Reduction, Ends Phase II Study

Flex Pharma (FLKS) announced that the company is ending the phase II studies for its pipeline candidate FLX-787 in two indications. The company also plans to lower its workforce by about 60%. F.....»»

Category: smallbizSource: nytJun 14th, 2018

Flex Pharma to end Phase 2 trials, explore alternatives, cut workforce

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 13th, 2018

Forty Seven Announces Potential Pricing for IPO

Clinical-stage immuno-oncology company Forty Seven intends to price more than 6 million shares so that the entire offering is valued up to more than $123 million......»»

Category: blogSource: 247wallstJun 18th, 2018

Mid-Day Market Update: Pivotal Software Gains Following Q1 Results; Flex Pharma Shares Slide

Midway through trading Wednesday, the Dow traded up 0.08 percent to 25,340.76 while the NASDAQ climbed 0.41 percent to 7,735.18. The S&P also rose, gaining 0.12 percent to 2,790.15. read more.....»»

Category: blogSource: benzingaJun 13th, 2018

Flex Pharma to cut more than half its workforce, end a phase 2 trial

Fl.....»»

Category: topSource: marketwatchJun 13th, 2018

Flex Pharma to reduce workforce by approximately 60%

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 13th, 2018

Flex Pharma closing trials due to oral tolerability concerns observed in studies

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 13th, 2018

Flex Pharma says ending ongoing Phase 2 FLX-787 trials in ALS, CMT

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 13th, 2018

The Week Ahead In Biotech: Conferences, Clinical Trials And IPOs

The ASCO conference closed Tuesday, although presentations at the conference triggered some huge stocks moves. read more.....»»

Category: blogSource: benzingaJun 10th, 2018

Mid-Day Market Update: Lululemon Surges After Strong Q1 Results; Kitov Pharma Shares Plunge

Midway through trading Friday, the Dow traded up 0.76 percent to 24,600.23 while the NASDAQ climbed 1.23 percent to 7,533.59. The S&P also rose, gaining 0.91 percent to 2,729.96. read more.....»»

Category: blogSource: benzingaJun 1st, 2018

Cara Therapeutics Shares Jump On Licensing Deal For Pruritis Treatment

Shares of Cara Therapeutics Inc (NASDAQ: CARA) are surging to a three-month high in reaction to a licensing agreement the biotech company announced with Vifor Fresenius Medical Care Renal Pharma. read more.....»»

Category: blogSource: benzingaMay 23rd, 2018

Alpine Is A Buy Ahead Of Clinical Trials, Wedbush Says In Positive Initiation

Wedbush analysts see an attractive entry point for Alpine Immune Sciences Inc. (NASDAQ: ALPN), as the biotech's initial candidates will enter the clinic over the next year. Latest Ratings fo.....»»

Category: blogSource: benzingaMay 18th, 2018

Loxo Oncology announces details of LOXO-292 clinical trials at ASCO

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMay 16th, 2018

The Week Ahead In Biotech: PDUFA Dates, Clinical Trials, Merck And Pfizer Earnings On Tap

After a lackluster show mid-way through the week despite M&A news and earnings, the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB) staged a recovery in the later part of the week. read more.....»»

Category: blogSource: benzingaApr 29th, 2018

The Week Ahead In Biotech: PDUFA Dates, Clinical Trials, Merck And Pfizer Earnings On Tap

After a lackluster show mid-way through the week despite M&A news and earnings, the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB) staged a recovery in the later part of the week. As the sector struggle.....»»

Category: earningsSource: benzingaApr 29th, 2018

Biotech Analysis Central Pharma News: Takeda Raises Shire Bid, Daiichi Fails DMD Trial, Celldex Cuts 20% Of Workforce

Biotech Analysis Central Pharma News: Takeda Raises Shire Bid, Daiichi Fails DMD Trial, Celldex Cuts 20% Of Workforce.....»»

Category: topSource: seekingalphaApr 26th, 2018

Can Epizyme Survive This FDA Hold?

Epizyme shares tumbled on Tuesday after the FDA announced a partial clinical hold affecting new enrollment of patients in the firm's tazemetostat trials......»»

Category: blogSource: 247wallstApr 24th, 2018

Unity Biotech Announces Potential Pricing for IPO

Unity Biotechnology plans to offer 5 million shares in an initial public offering valued up to more than $103 million......»»

Category: blogSource: 247wallstApr 24th, 2018

Biotech Analysis Central Pharma News: Orexigen"s Last Resort, Epizyme"s Partial Clinical Hold, Eli Lilly And Incyte"s Mixed Advisory Panel Vote

Biotech Analysis Central Pharma News: Orexigen"s Last Resort, Epizyme"s Partial Clinical Hold, Eli Lilly And Incyte"s Mixed Advisory Panel Vote.....»»

Category: topSource: seekingalphaApr 24th, 2018

Q2 2018 Biotech Catalyst Watchlist: Phase 2 Clinical Trials

Q2 2018 Biotech Catalyst Watchlist: Phase 2 Clinical Trials.....»»

Category: topSource: seekingalphaApr 19th, 2018